Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Multiple Myeloma 3Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Mouth Neoplasms 2Head and Neck Neoplasms 2Weight Loss 1Urinary Bladder Neoplasms 1Tobacco Use Cessation 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Smoking Cessation 1Neoplasm Metastasis 1Meningioma 1Lymphocytosis 1Lymphadenopathy 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gynecologic Oncology Patient 1Gastrointestinal Neoplasms 1Fever 1Fatigue 1Fallopian Tube Neoplasms 1Depression 1Dental Caries 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

enfortumab vedotin 1durvalumab 1cemiplimab 1advexin 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Nivolumab 1Magnetic Resonance Imaging 1Histamine Antagonists 1Electrocardiography 1Diphenhydramine 1Cystoscopy 1Cholecalciferol 1Blood Specimen Collection 1Acetaminophen 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma in Situ × Surveys and Questionnaires × Clear all
NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡